Germany's drug industry to hit $63.5B by 2013

The German pharmaceutical industry will experience moderate growth in the next few years, according to research by market analyst firm  Decision Resources, reaching $63.5 billion by 2013, of $770 per capita.  One of the positive effects introduced by the government, a cut in  value-added tax, will contribute by lowering prices without hitting  manufacturers' revenue, the firm argues.

Other factors affecting Germany's drug market are the presence of a  highly-developed generic sector and an aging population, the latter  tending to increase demand, especially for chronic conditions, such as  diabetes.